Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Aptose Biosciences Inc. (T:APS)

Business Focus: Biotechnology & Medical Research

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for APS within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Oct 19, 2020 07:00 ET
Aptose Initiates Dosing of CG-806 in Patients with Acute Myeloid Leukemia
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced dosing of the first patient with acute...
Read full article
Sep 15, 2020 07:30 ET
Aptose to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.79
--
--
Price to Sales - TTM
--
17.67
10.84
Price to Book - most recent quarter
4.60
4.02
2.94
Price to Cash Flow per share - TTM
--
13.31
11.51
Price to Free Cash Flow per share - TTM
--
30.73
17.74
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Oct 15, 2020466,29639,877
Sep 30, 2020426,4191,337
Sep 15, 2020425,082-17,103
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company's APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.

See business summary

 

Twitter

Search (past week) for $APS.CA

  • No tweets found